Trudeau announces plan to purchase 76 million doses of Canadian-made COVID-19 vaccine
Canada has announced another commitment of COVID-19 vaccine doses, this time for the candidate being developed by Quebec-based Medicago and multinational GlaxoSmithKline. While still in pre-clinical studies, researchers are optimistic about the level of neutralizing antibodies observed following a single dose. The deal secures 76 million doses of the candidate if it receives regulatory approval. Canada has invested $173 million to assist Medicago with development and production capacity of the vaccine, and this deal represents the seventh commitment of vaccine candidates from various manufacturers should they receive regulatory approval.
Published: October 23, 2020